Silexion Therapeutics CORP

Silexion Therapeutics Corp. has appointed Avner Lushi to its Audit Committee, restoring full compliance with Nasdaq listing rules following a prior director's resignation.

Silexion Therapeutics Corp. announced the resignation of Professor Amnon Peled from its Board of Directors, effective August 1, 2026, due to personal reasons.

Silexion Therapeutics has successfully initiated its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, marking a transition to active clinical execution.

Silexion Therapeutics Corp shareholders approved an increase in authorized share capital and the exercisability of certain warrants.

Silexion Therapeutics Corp implemented a 1-for-10 reverse share split and adjusted warrants to maintain Nasdaq listing compliance.

Silexion Therapeutics Corp. announced a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and support its ongoing development of RNAi therapies.

Silexion Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of SIL204 and significant capital raising efforts to address going concern risks.

Silexion Therapeutics Corp. reported a significant reduction in net loss and a substantial increase in cash reserves for the nine months ended September 30, 2025, while addressing Nasdaq listing compliance and ongoing financing needs.

Silexion Therapeutics reported an increased net loss in Q2 2025, actively pursuing multiple financing strategies and navigating Nasdaq listing compliance challenges.

Silexion Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Silexion Therapeutics Corp reports its Q3 2024 results, reflecting the impact of its recent business combination and ongoing development of its cancer treatments.

Silexion Therapeutics, a clinical-stage biotechnology company, reported increased net losses for the second quarter of 2024 as it continues to invest heavily in the research and development of its lead pancreatic cancer treatment candidate, SIL-204B.

Silexion Therapeutics Corp files an amendment to its 2025 annual report to correct internal control reporting dates.

Silexion Therapeutics Corp reports significant losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead oncology candidate, SIL204, towards Phase 2/3 clinical trials.

Silexion Therapeutics Corp outlines its share capital, warrant details, and corporate governance in its latest 10-K filing, highlighting key aspects of its securities registered under the Exchange Act.

Silexion Therapeutics Corp. officer Mitchell Shirvan reports acquisition of 6,000 ordinary shares via settled RSUs and provides updated derivative security ownership following a 1-for-10 reverse stock split.

Hadar Mirit Horenshtein, CFO and Secretary of Silexion Therapeutics Corp, was granted 7,500 ordinary shares via fully vested restricted stock units.

Ilan Hadar, Director and CEO of Silexion Therapeutics Corp, reported a grant of restricted share units settled into ordinary shares and provided updated beneficial ownership following a reverse stock split.

A fund associated with Silexion Therapeutics Corp director Shlomo Noy acquired ordinary shares and stock options for director services.

Silexion Therapeutics Corp director Ruth Alon was granted 9,091 ordinary shares and options to purchase 10,685 ordinary shares for her services.

Silexion Therapeutics' Chief Scientific and Development Officer, Mitchell Shirvan, reported the acquisition of 49,726 ordinary shares through an RSU grant, following two significant reverse share splits.

Silexion Therapeutics Corp is holding an extraordinary general meeting to approve warrant exercisability and an increase in authorized share capital to maintain Nasdaq compliance.

Silexion Therapeutics Corp. is holding an extraordinary general meeting on April 28, 2026, to seek shareholder approval for proposals including an increase in authorized share capital, an amendment to its equity incentive plan, and a reverse stock split.

Silexion Therapeutics Corp. calls an extraordinary general meeting to approve a significant increase in authorized share capital and an expanded equity incentive plan to maintain Nasdaq listing and fund operations.

Silexion Therapeutics Corp. adjourned its extraordinary general meeting to August 19, 2025, to vote on increasing authorized share capital to meet Nasdaq listing requirements and enable future equity raises.

Silexion Therapeutics Corp. is seeking shareholder approval to significantly increase its authorized share capital to meet Nasdaq listing requirements and fund the development of its RNAi therapies.

A clinical-stage biotechnology company has adjourned its annual general meeting to July 14, 2025, and set a 1-for-15 reverse share split ratio to regain Nasdaq listing compliance and facilitate future capital raising.

Silexion Therapeutics Corp files an S-1 for a best-efforts public offering of up to 832,177 ordinary shares and warrants, while addressing significant operating losses and Nasdaq listing compliance challenges.

Silexion Therapeutics Corp filed an S-1 registration statement for the resale of ordinary shares, highlighting significant operating losses, a going concern doubt, and recent capital raises to fund its clinical-stage oncology programs.

Silexion Therapeutics is amending its S-1 registration statement to allow selling securityholders to resell up to 2,377,030 ordinary shares following a 1-for-9 reverse stock split.

Silexion Therapeutics is registering for resale up to 2.38 million ordinary shares by selling securityholders, primarily from warrant exercises.

Silexion Therapeutics launches a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies, including SIL-204B for pancreatic cancer.

Silexion Therapeutics is launching a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies.

Moringa Sponsor, LP filed an amendment to its Schedule 13D, formally disputing the validity of recent share issuances by Silexion Therapeutics Corp.

Moringa Sponsor, LP disputes the validity of 450,000 ordinary shares issued by Silexion Therapeutics Corp from a $1.8 million debt conversion.

Wildcat Capital Management, LLC and its affiliates have reported a decreased beneficial ownership percentage in Silexion Therapeutics Corp to 1.3% due to an increase in the issuer's outstanding ordinary shares.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.4% beneficial ownership stake in Silexion Therapeutics Corp.

Lind Global Fund III LP and affiliates reported a 6.4% beneficial ownership stake in Silexion Therapeutics Corp, primarily through warrants.

Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have disclosed a 9.9% beneficial ownership stake in Silexion Therapeutics Corp.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% passive beneficial ownership in Silexion Therapeutics Corp. ordinary shares.

Orca Capital AG has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Silexion Therapeutics Corp, holding 109,432 ordinary shares.

Orca Capital AG has reported a 6.2% beneficial ownership stake in Silexion Therapeutics Corp, holding 131,250 ordinary shares.